newsfilter
← Latest News
Business Wire·

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease

Alpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the